ClinVar Miner

Submissions for variant NM_000432.4(MYL2):c.173G>A (p.Arg58Gln) (rs104894369)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000844711 SCV000060038 pathogenic Hypertrophic cardiomyopathy 2018-01-24 criteria provided, single submitter clinical testing The p.Arg58Gln variant in MYL2 has been reported in at least 16 individuals with HCM and segregated with disease in 11 affected relatives from 6 families (Flavi gny 1998, Kabaeva 2002, Morner 2003, Olivotto 2011, Li 2015, Walsh 2016, LMM dat a). It has also been identified in 2/22298 Finnish chromosomes by the Genome Agg regation Database (gnomAD, http://exac.broadinstitute.org; dbSNP rs104894369). T his variant was predicted to be pathogenic using a computational tool clinically validated by our laboratory. This tool's pathogenic prediction is estimated to be correct 94% of the time (Jordan 2011). In vitro functional studies provide so me evidence that the p.Arg58Gln variant may impact protein function (Szczesna 20 01,Szczesna-Cordary 2004, Greenberg 2009, Greenberg 2010, Mettikolla 2011, Wang 2013). In summary, this variant meets criteria to be classified as pathogenic fo r HCM in an autosomal dominant manner. ACMG/AMP Criteria applied: PS4; PP1_Stron g; PM2; PS3_Moderate; PP3.
GeneDx RCV000158923 SCV000208858 pathogenic not provided 2018-11-13 criteria provided, single submitter clinical testing The R58Q pathogenic variant in the MYL2 gene has been reported previously in association with HCM (Flavigny et al., 1998; Kabeva et al., 2002; Richards et al., 2003; Morner et al., 2003). Flavigny et al. (1998) initially identified the R58Q variant in two unrelated individuals with HCM, and this variant was present in an affected relative of one of these individuals. Morner et al. (2003) also reported the R58Q pathogenic variant co-segregated with an HCM phenotype in one family, noting the incomplete penetrance and variable expressivity of this variant given the proband developed HCM at age 67, the proband's daughter carried the R58Q variant and remained unaffected, and the proband's affected granddaughter developed HCM at age 18. Additionally, the R58Q variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016). The R58Q variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties, and it occurs at a position that is conserved across species (Flavigny et al., 1998; Szczesna-Cordary et al., 2004). Furthermore, functional studies of this variant indicate the R58 residue is in a calcium binding site within the human cardiac regulatory light chain and R58Q eliminates normal calcium binding and increases the calcium sensitivity of myofibrillar ATPase, which is proposed to affect regulation of cardiac muscle contraction (Szczesna et al., 2001; Szczesna-Cordary et al., 2004; Greenberg et al., 2009; Wang et al., 2013).
Invitae RCV000015111 SCV000549157 pathogenic Familial hypertrophic cardiomyopathy 10 2020-10-13 criteria provided, single submitter clinical testing This sequence change replaces arginine with glutamine at codon 58 of the MYL2 protein (p.Arg58Gln). The arginine residue is highly conserved and there is a small physicochemical difference between arginine and glutamine. This variant is present in population databases (rs104894369, ExAC 0.02%). This variant has been reported in multiple individuals and families affected with hypertrophic cardiomyopathy (HCM) (PMID: 9535554, 12404107, 12818575, 23283745, 24111713). ClinVar contains an entry for this variant (Variation ID: 14067). Experimental studies have shown that this missense change increases the Ca2+ sensitivity and reduces myosin maximal force production (PMID: 14594949, 19150977, 20855589, 21723297, 23727233, 26116789). For these reasons, this variant has been classified as Pathogenic.
Fulgent Genetics,Fulgent Genetics RCV000015111 SCV000611288 pathogenic Familial hypertrophic cardiomyopathy 10 2017-05-18 criteria provided, single submitter clinical testing
Ambry Genetics RCV000621867 SCV000740066 likely pathogenic Cardiovascular phenotype 2018-11-20 criteria provided, single submitter clinical testing The p.R58Q variant (also known as c.173G>A), located in coding exon 4 of the MYL2 gene, results from a G to A substitution at nucleotide position 173. The arginine at codon 58 is replaced by glutamine, an amino acid with highly similar properties. This alteration has been reported in multiple individuals with hypertrophic cardiomyopathy while absent in controls (Flavigny J et al. J. Mol. Med., 1998 Mar;76:208-14; Kabaeva ZT et al. Eur. J. Hum. Genet., 2002 Nov;10:741-8; Richard P et al. Circulation, 2003 May;107:2227-32; Mörner S et al. J. Mol. Cell. Cardiol., 2003 Jul;35:841-9; Lopes LR et al. Heart, 2015 Feb;101:294-301). One study reported this variant to co-segregate with disease in two families, but complete pedigrees were not provided (Flavigny J et al. J. Mol. Med., 1998 Mar;76:208-14). Another study reported this alteration in a proband, affected granddaughter, and asymptomatic daughter, suggesting possible incomplete penetrance and variable expressivity (Mörner S et al. J. Mol. Cell. Cardiol., 2003 Jul;35:841-9). In addition, a number of in vitro studies suggested that this variant would abolish calcium binding and alter the contraction kinetics of cardiac muscle (Szczesna D et al. J. Biol. Chem., 2001 Mar;276:7086-92; Greenberg MJ et al. J. Mol. Cell. Cardiol., 2009 Jan;46:108-15; Greenberg MJ et al. Proc. Natl. Acad. Sci. U.S.A., 2010 Oct;107:17403-8; Wang Y et al. J. Mol. Biol., 2006 Aug;361:286-99; Mettikolla P et al. J. Theor. Biol., 2011 Sep;284:71-81; Wang L et al. J. Mol. Cell. Cardiol., 2013 Sep;62:153-63). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the majority of available evidence to date, this variant is likely to be pathogenic.
OMIM RCV000015111 SCV000035368 pathogenic Familial hypertrophic cardiomyopathy 10 2002-11-01 no assertion criteria provided literature only
Leiden Muscular Dystrophy (MYL2) RCV000015111 SCV000045757 not provided Familial hypertrophic cardiomyopathy 10 2012-03-26 no assertion provided curation
Blueprint Genetics RCV000157369 SCV000207107 pathogenic Primary familial hypertrophic cardiomyopathy 2014-07-21 no assertion criteria provided clinical testing
Stanford Center for Inherited Cardiovascular Disease, Stanford University RCV000158923 SCV000280383 likely pathogenic not provided 2015-02-03 no assertion criteria provided clinical testing Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. p.Arg58Gln (p.R58Q; c.173G>A) in the MYL2 gene (NM_000432.3) The variant has been seen in at least 8 unrelated cases of HCM (one of them is another patient at SCICD). There is weak segregation in at least two families. The Arg58Gln variant was first reported in association with HCM in two unrelated individuals and it was also present in an affected relative of one of these individuals (Flavigny et al., 1998). Kabaeva et al., 2002 (last author Osterziel) reported this variant in one individual with HCM. The proband had non-obstructive HCM first diagnosed at the age of 7 years. She underwent implantation of an ICD at age 25 years after VT degenerating into VF was observed. She had recurrent episodes of supraventricular tachycardia. No segregation data was available as her family members with HCM (father and sister) had sudden cardiac deaths at young ages and DNA was not available, however the proband's mother tested negative suggesting that this variant was paternally inherited and therefore more likely to be a disease-causing variant in the family. The pattern of LV hypertrophy was reportedly similar to the cases presented by Flavigny et al. Olivotto et al., 2008 (last author Cecchi) reported this variant in two individuals with HCM. Additional details regarding their phenotype were not given. Richard et al., 2003 reported this variant in one individual with HCM. Additional phenotype or segregation details were not given. Harvard’s Laboratory for Molecular Medicine submitted this variant to ClinVar on 1/29/2015. They classify it as pathogenic, and report seeing it in 5 families. Arg58Gln results in a non-conservative amino acid substitution of a positively charged Arginine with a neutral, polar Glutamine at a residue that is conserved across species. This variant is located in exon 4 of 7 exons. Functional studies of this variant indicate that it is in a calcium binding site within the human cardiac regulatory light chain and Arg58Gln eliminates normal calcium binding and increases the calcium sensitively of myofibrillar ATPase, which is proposed to affect regulation of cardiac muscle contraction (Szczesna-Cordary et al., 2004). In silico analysis with PolyPhen-2 predicts the variant to be probably damaging. The arginine at codon 58 is conserved across vertebrate species, however it is a glutamine in C-elegans. Neighboring amino acids are conserved. No other variants have been associated with disease at this codon. A neighboring codon, p.Gly57Glu, has been reported in one individual with RCM; she was also found to be homozygous for a variant in MYL3, p.Glu143Lys. HGMD also includes a nearby variant (+/- 10) Glu65Lys associated with HCM. In total the variant has been seen in just 1 out of ~60,000 laboratory controls, published controls and individuals from publicly available population datasets. There is no variation at codon 58 listed in the NHLBI Exome Sequencing Project dataset, which currently includes variant calls on ~6,500 Caucasian and African American individuals (as of 1/26/2015). Note that this dataset does not match the patient's ancestry. The variant was not observed in the following laboratory and published control samples: absent 150 individuals (Olivotto et al.), absent in 100 individuals (Morner et al), absent in 105 individuals (Richard et al), and 100 individuals (Kabeava et al.). The ethnicities of these individuals are not known.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.